Seismic Therapeutic Forms Translational Medicine Advisory Board with Prominent Experts in Immunology, Rheumatology, Dermatology and Neurology

Watertown, Mass., March 18, 2025 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced the formation of a Translational Medicine Advisory Board to support the company’s focus on accelerating the path to impactful, patient-centric therapies for autoimmune and inflammatory diseases. The charter members of Seismic’s Translational Medicine Advisory Board are J. Michelle Kahlenberg, MD, PhD, Gerald Nepom, MD, PhD, Kevin O’Connor, PhD, and Cornelia Weyand, MD, PhD. These distinguished experts bring decades of combined experience and leadership in their respective fields of immunology, rheumatology, dermatology and neurology and will provide strategic guidance as the company advances its pipeline of innovative medicines in clinical trials for immune-driven diseases. They are complemented by additional expert advisors in relevant specialty areas.

“We are honored to welcome this exceptional group of advisors whose expertise will contribute valuable insights as we continue to advance our innovative biologics into the clinic,” said John Sundy, MD, PhD, Chief Medical Officer and Head of R&D for Seismic Therapeutic. “Each member brings a wealth of experience from bench-to-bedside in a range of disease areas, supporting our mission to rapidly bring a new era of medicines for autoimmune and inflammatory diseases to improve outcomes for patients.”

About Seismic Therapeutic
Seismic Therapeutic™ is a clinical-stage biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.

 

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investor Contact
Emiley Demick, Precision AQ (formerly Stern IR)
212-362-1200
emiley.demick@precisionaq.com

 
 

This links to an external website.

Continue